Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | CHIEF MEDICAL OFFICER | January 21, 2026 | January 23, 2026 |
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Sr. VP, Clinic. Devel. & CMO | April 02, 2019 | April 04, 2019 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Chief Medical Officer | February 10, 2021 | February 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2036-01-20 | Direct | 250,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 6,136 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 72,620 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 110,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-02 · Disposition to issuer · Disposed 113,335 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-02 · Disposition to issuer · Disposed 110,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards.
F3: Not Applicable.
F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share.
Nuvation Bio Inc.
Report date February 10, 2021 · Filed February 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 · Expires 2030-10-04 | Direct | 398,935 |
Reported balance
After 2021-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-10 · Grant · Acquired 398,935 · Balance 398,935 F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-01-21 | Direct | 398,935 |
Reported balance
After 2021-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-10 · Grant · Acquired 398,935 · Balance 398,935 F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F4: Options vest as to 25% on September 17, 2020 and in equal monthly installments thereafter over the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer").
F2: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria.
F3: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock.
F4: Options vest as to 25% on September 17, 2020 and in equal monthly installments thereafter over the following three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001686295-26-000002 · form4-01232026_040104.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001415889-25-002493 · form4-01312025_090152.xml · derivative · entry 2 Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-01-29 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002493 · form4-01312025_090152.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:37 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001415889-24-003967 · form4-02152024_100227.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:12 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022391 · tm236831-6_4seq1.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010332 · doc4.xml · derivative · entry 2 Yurasov Sergey · CIK 0001686295 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on September 17, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010332 · doc4.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:16 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 110,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023688 · doc4.xml · derivative · entry 5 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:16 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 113,335 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-19-023688 · doc4.xml · derivative · entry 4 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,335 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:16 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 110,000 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-023688 · doc4.xml · derivative · entry 3 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:16 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerRestricted Stock Units · Derivative | 72,620 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-19-023688 · doc4.xml · derivative · entry 2 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,620 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:16 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerCommon Stock | 6,136 | $5.85 | $35,895.60 |
DisclosureSEC source: 0001209191-19-023688 · doc4.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 20:34 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 3,522 | $1.57 | $5,535.53 |
DisclosureSEC source: 0001209191-19-002669 · doc4.xml · nonDerivative · entry 2 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,756 F3 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.5635 to $1.621 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:34 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-19-002669 · doc4.xml · derivative · entry 3 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2029-01-03 F5 · derivative.exercise_date: One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:34 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002669 · doc4.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,278 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 16:13 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 29,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057941 · doc4.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,278 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: Restricted stock units shall vest in a single installment on November 7, 2019, subject to the Reporting Person's continuous service through such date. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 19,584 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 8 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,584 Underlying: Common Stock · 19,584 shares Expires 2025-07-17 F8 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 29,375 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 19,584 shares, having an exercise price of $4.40 per share. F7 · derivative.exercise_date: The option vests in thirty six (36) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 29,375 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 7 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,375 shares Expires 2027-01-04 F8 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 29,375 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 19,584 shares, having an exercise price of $4.40 per share. F5 · derivative.exercise_date: The option provided for 1/4th of the shares underlying the option on January 4, 2018 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 417 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 6 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Underlying: Common Stock · 417 shares Expires 2025-07-17 F6 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 625 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 417 shares, having an exercise price of $4.40 per share. F7 · derivative.exercise_date: The option vests in thirty six (36) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 625 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 5 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires 2027-01-04 F6 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 625 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 417 shares, having an exercise price of $4.40 per share. F5 · derivative.exercise_date: The option provided for 1/4th of the shares underlying the option on January 4, 2018 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 58,155 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 4 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,155 Underlying: Common Stock · 58,155 shares Expires 2025-07-17 F4 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,232 shares of the issuer's common stock granted to the reporting person on November 1, 2016. In exchange, the reporting person received a replacement option, for 58,155 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 87,232 | Not disclosed Strike: $7.58 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 3 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,232 shares Expires 2025-10-01 F4 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,232 shares of the issuer's common stock granted to the reporting person on November 1, 2016. In exchange, the reporting person received a replacement option, for 58,155 shares, having an exercise price of $4.40 per share. F1 · derivative.exercise_date: The option provided for vesting of 1/4th of the shares underlying the option on October 1, 2017 and the remainder of the shares at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 35,179 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 2 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,179 Underlying: Common Stock · 35,179 shares Expires 2025-07-17 F2 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 52,768 shares of the issuer's common stock granted to the reporting person on October 1, 2016. In exchange, the reporting person received a replacement option, for 35,179 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:01 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 52,768 | Not disclosed Strike: $7.58 | Not disclosed |
DisclosureSEC source: 0001209191-18-043393 · doc4.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,768 shares Expires 2025-10-01 F2 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 52,768 shares of the issuer's common stock granted to the reporting person on October 1, 2016. In exchange, the reporting person received a replacement option, for 35,179 shares, having an exercise price of $4.40 per share. F1 · derivative.exercise_date: The option provided for vesting of 1/4th of the shares underlying the option on October 1, 2017 and the remainder of the shares at a rate of 1/36th per month thereafter. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 20:16 UTC Amendment | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 675 | $4.17 | $2,816.44 |
DisclosureSEC source: 0001209191-18-002807 · doc4a.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,325 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018. F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018. F2 · balance_after: On January 5, 2018, the reporting person filed a Form 4 that inadvertently reported (i) an incorrect transaction date and (ii) omitted an applicable footnote referring to the fact that the shares were sold pursuant to a current 10b5-1 trading plan. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 18:30 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-18-002547 · doc4.xml · derivative · entry 3 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-01-04 F3 · derivative.exercise_date: One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 18:30 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 675 | $4.17 | $2,816.44 |
DisclosureSEC source: 0001209191-18-002547 · doc4.xml · nonDerivative · entry 2 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,325 Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 18:30 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002547 · doc4.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 20:51 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002792 · doc4.xml · derivative · entry 2 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-04 F3 · derivative.exercise_date: One quarter of the shares underlying the option will vest on January 4, 2018, and the remainder of the shares underlying the option will vest at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 20:51 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002792 · doc4.xml · nonDerivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: One quarter of the total restricted stock units vest annually beginning January 4, 2018, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 16:35 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-16-144286 · doc4.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · Sr. VP, Clinic. Devel. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2026-10-01 F1 · derivative.exercise_date: One quarter of the shares underlying the option will vest on October 1, 2017, and the remainder of the shares underlying the option will vest monthly in equal installments at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.